Overview

A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the Maximum Tolerated Dose and the Dose-Limiting Toxicity of the drug to further evaluate safety and antitumor activity.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Proacta, Incorporated